LA ALOPECIA ANDROGÉNICA Y SUS ALTERNATIVAS TERAPÉUTICAS. !
ANDROGENIC ALOPECIA AND THERAPEUTIC ALTERNATIVES. !
ACTUALIZADO 2025
EDITORIAL ESPAÑOL:
==================
Hola amigos de la red DERMAGIC EXPRESS hoy con otro tema interesante,
actualmente muy discutido y estudiado:
ALOPECIA ANDROGÉNICA, Y SUS ALTERNATIVAS TERAPÉUTICAS.
La
ALOPECIA ANDROGENICA
(AGA), el tipo más común de pérdida de cabello, se produce en 80% de
los hombres y 50% de las mujeres, fundamentalmente de índole genético
y hormonal.
1.) HISTORIA:
- En
Egipto antiguo
( 1500 años A.C.), ya se conocía la calvicie masculina, y en textos como el
Papiro Ebers
recomendaban remedios caseros como: cebolla, grasa de león, de
hipopótamo y excremento de murciélagos.
- Hipócrates de Cos
( 460-370 años A.C.),
médico griego considerado padre de la medicina occidental de Grecia,
describió la calvicie masculina y notó su ausencia en eunucos,
(masculinos con extirpación de genitales INCAPACES de producir la
hormona
TESTOSTERONA.
-
James B. Hamilton
(1909-1990):
dermatólogo estadounidense de Nueva York, estableció en 1942 la relación
entre la alopecia androgenica con los andrógenos al estudiar
eunucos, y estableció la primera clasificación de esta patología en 5
tipos.
-
O'Tar T. Norwood
(1920-2022): dermatólogo estadounidense de Oklahoma especializado en
trasplantes capilares, modificó y amplió la escala a 7 tipos en 1975,
luego de analizar 1000 (mil) casos.
-
Erich Ludwig: dermatólogo alemán especializado en tricología y enfermedades del
cabello, quien en 1977 desarrolla una escala simplificada de la calvicie
en las mujeres, en 3 grados, basado en el hecho de que la perdida
de cabello en la mujer es difusa y central, a diferencia de los hombres
que presentan diferentes patrones.
2.) CLASIFICACIÓN:
A.) Hombres: (Escala
Norwood-Hamilton, 7 tipos):
- TIPOS:
I: Línea frontal normal.
II: Retroceso leve bifrontal.
III: Entradas profundas (±vertex).
IV: Avance frontal + calvicie parcial vertex.
V: Mayor pérdida, puente mínimo.
VI: Fusión frontal-vertex.
VII: Cabello en "U" posterior (80% de los casos).
B.) Mujeres: (Escala Ludwig, 3 grados):
I: Rarefacción central leve.
II: Moderada con partición ensanchada.
III: Avanzada, posible calvicie total central.
Esta clasificación es con fines educativos, y de comprensión, que pueden orientar al medico tratante a escoger el método mas adecuado para tratar la patología; en mujeres predomina el PATRON DIFUSO, en masculinos el PATRON mas común es la ALOPECIA EN "U", con un 80% de los casos (areas con calvicie desde la region frontal hasta media region occipital, respetando areas laterales temporales y parietales.
2.) ETIOLOGÍA:
- Primeramente hay que explicar a la audiencia NO MEDICA, que la alopecia androgenica es la perdida del cabello producida por un aumento de los ANDRÓGENOS, (principalmente la testosterona), en nuestro cuerpo, tanto en el hombre como la mujer. específicamente su metabolito o derivado llamado: DIHIDROTESTOSTERONA.
- Este exceso de ANDRÓGENOS específicamente la DIHIDROTESTOSTERONA, se depositan en el folículo piloso y lo atrofian, provocando la caída del cabello. Este es el mecanismo principal que ocasiona LA ALOPECIA ANDROGÉNICA.
- Caracterizada por una caída del cabello progresiva, que afecta tanto hombres como mujeres post puberales, la cual puede llegar a ser severa en ambos sexos.
- En la mujer enfermedades como el
SÍNDROME DE OVARIO POLIQUISTICO, produce aumento de los andrógenos con la subsecuente caída del
cabello.
- En el hombre, la enfermedad tiene sin duda un componente genético, porque no todo el mundo está afectado, y es importante que usted sepa que, hay hombres que NUNCA SUFRIRÁN DE ALOPECIA ANDROGÉNICA, generalmente siempre hay un historial de calvicie en los afectados.
- En el hombre, la enfermedad tiene sin duda un componente genético, porque no todo el mundo está afectado, y es importante que usted sepa que, hay hombres que NUNCA SUFRIRÁN DE ALOPECIA ANDROGÉNICA, generalmente siempre hay un historial de calvicie en los afectados.
3.) EVOLUCIÓN:
- Aquí hay que explicar que el cabello no esta "ADHERIDO CON PEGAMENTO" al cuero cabelludo, tiene un ciclo de de "VIDA: ANAGENO, o crecimiento, dura de 1 a 7 años, CATAGENO, o de transición, que dura de 2 a 3 meses y TELOGENO o de reposo la cual dura unos 3 meses aproximadamente, luego el cabello se cae y es sustituido por uno nuevo.
- NORMALMENTE SE CAEN ENTRE 50 Y 100 CABELLOS DIARIOS.
- Es interesante que también sepas que cuando el cuerpo esta sometido a un gran ESTRÉS, y otros factores el cabello entra prematuramente en FASE TELOGENA y comienza a caerse abundantemente produciendo una notable ALOPECIA.
- De modo que factores como el ESTRÉS y otros que alteren el CICLO del cabello contribuirán a que la ALOPECIA ANDROGÉNICA sea mayor.
- Otro factor que que empeora LA ALOPECIA ANDROGÉNICA ES LA DERMATITIS SEBORREICA del cuero cabelludo, comúnmente denominada "AUMENTO DE LA GRASA EN EL CABELLO, de modo que mientras mas uses un champú anti caspa, MENOS SEBORREA habrá, por lo tanto menos caída del cabello.
4.) TRATAMIENTOS:
Tratamientos para LA ALOPECIA ANDROGÉNICA hay variados, y te resalto los mas utilizados hoy dia:
1.) MINOXIDIL, TÓPICO (ANTIHIPERTENSIVO).
2.) FINASTERIDE (INHIBIDOR DE LA 5-ALFA REDUCTASA).
3.) DUTASTERIDE (INHIBIDOR DE LA 5-ALFA REDUCTASA).
4.) FLUTAMIDA (INHIBIDOR DE LA 5-ALFA REDUCTASA).
5.) CYPROTERONA ACETATO (ANTICONCEPTIVO ORAL).
6.) ESPIRONOLACTONA (ANTIDIURETICO ORAL).
7.) SERENOA REPENS O PALMETTO SAW (NATURISTA, ANTI-ANDROGENO).
8.) CYPERUS ROTUNDUS (NATURISTA).
9.) ESTEROIDES TÓPICOS.
10.) CHAMPU ANTI-CASPA. (KETOCONAZOL, PIRITIONATO DE ZINC, BIFONAZOL)
11.) DROSPIRENONA (ANTICONCEPTIVO ORAL).
5.) NUEVOS TRATAMIENTOS:
A.- TÓPICOS:
- FINASTERIDE TOPICO al 0.25%: Salio al mercado en Noviembre del 2024 con el nombre de
FINASTOPIC, del laboratorio
ISDIN de España. Esta alternativa se venia buscando desde los años 2000, y tiene la
ventaja sobre el FINASTERIDE en pastillas, de minimizar los efectos
secundarios.
- CLASCOTERONE 5%: con los nobres comerciales de
Breezula y Winlevi: Antagonista tópico del receptor androgénico (AR), bloquea la
DIHIDROTESTOSTERONA localmente sin efectos sistémicos; el producto NO
ESTA APROBADO; se encuentra en fase III.
B.- NO TOPICOS:
- PRP optimizado (iPRF):
Plasma rico en fibrina con células madre; 4-6 sesiones anuales, para aumentar el grosor capilar.
- Minoxidil oral microdosis (0.25-5mg) + dutasterida
tópica.
-
Mesoterapia capilar:
Microinyecciones de vitaminas, péptidos, ácido hialurónico y
minoxidil.
-
Laser LLLT: Terapia de laser de baja intensidad, aprobado por la
FDA
para el tratamiento de la alopecia androgenica, año 2007, considerado un
dispositivo seguro y efectivo. Los dispositivos de este tipo disponibles
son:
- cHairMax® LaserComb (Lexington International):
Primer dispositivo aprobado (2007). Es un peine láser de diodo
rojo (655 nm) para uso doméstico.
iRestore® Laser Growth System: Aprobado en 2016; se trata de un casco con 21 diodos y 30 LEDS infrarrojos.
- Capillus® / LaserCap® / Theradome®: Aprobados entre 2012 y 2018, se trata de laser tipo cascos gorras con frecuencia de 272-560 nm.
C.-
TRASPLANTE CAPILAR:
Los trasplantes capilares NO SON NUEVOS, comenzaron a usarse desde la
década de 1930, cuando el medico japones Dr. Shoji Okuda
desarrolló la técnica de injertos "punch" o "sacabocado" para restaurar
cabello en quemados y alopésicos.
- En la década de los 1950
el medico Americano Dr. Norman Orentreich
(EE.UU.) realizó el primer trasplante moderno para calvicie en 1952,
procedimiento tipo "punch"
- EVOLUCIÓN DE LA TÉCNICA HASTA 2025:
- 1950s-70s: Punch grafts
grandes (4-5mm), antiestéticos ("muñeco").
- 1980s-90s: Microinjertos (1-4 folículos) por Dr. Bobby Limmer (FUT).
- 2000s: FUE: (2002, Dr. Rassman/FUE Research Committee).
- 1980s-90s: Microinjertos (1-4 folículos) por Dr. Bobby Limmer (FUT).
- 2000s: FUE: (2002, Dr. Rassman/FUE Research Committee).
La técnica más utilizada hoy dia 2025, es la
FUE (Follicular Unit Extraction): Extrae folículos individuales (0.8-1mm) con punch
motorizado/robótico, no se extrae tira lineal de piel, tampoco deja
cicatriz visible, con un porcentaje del 80 90% de utilización global,
con rápida recuperación.
6.) CONCLUSIONES:
Existe en nuestro cuerpo una enzima denominada 5 alpha reductasa que es la encargada de convertir la TESTOSTERONA EN DIHIDROTESTOSTERONA. Al aumentar este metabolito, mayor sera la caída del cabello.
Por lo tanto una de las estrategias para evitar la ALOPECIA ANDROGENICA es inhibir la enzima 5 alfa-reductasa, y para ello ya se han inventado y descubierto medicinas farmacológicas y naturistas, estas son las ya mencionadas:
Existe en nuestro cuerpo una enzima denominada 5 alpha reductasa que es la encargada de convertir la TESTOSTERONA EN DIHIDROTESTOSTERONA. Al aumentar este metabolito, mayor sera la caída del cabello.
Por lo tanto una de las estrategias para evitar la ALOPECIA ANDROGENICA es inhibir la enzima 5 alfa-reductasa, y para ello ya se han inventado y descubierto medicinas farmacológicas y naturistas, estas son las ya mencionadas:
-
FINASTERIDE.
- DUTASTERIDE.
- FLUTAMIDA.
- SERENOA REPENS
O SAW PALMETTO (NATURISTA, ANTI-ANDROGENO).
- CYPERUS ROTUNDUS
(NATURISTA).
Todas estas medicinas tienen sus VENTAJAS y sus EFECTOS ADVERSOS, pero
si nos ubicamos en la realidad, la ciencia ha avanzado notablemente en
este campo, hace muchos años se decía popularmente:
" ...A LA CAÍDA DEL CABELLO SOLO LA DETIENE EL PISO O SUELO.."
" ...A LA CAÍDA DEL CABELLO SOLO LA DETIENE EL PISO O SUELO.."
Hoy dia este viejo adagio no es cierto, por la aparición de medicamentos principalmente como DUTASTERIDE, FINASTERIDE Y FLUTAMIDA, los cuales inhiben la enzima 5 alfa-reductasa, principal causante del aumento de los ANDRÓGENOS en nuestro cuerpo.
Ademas de ello la modernización de la TÉCNICA del micro injerto, donde se
trasplanta una unidad de cabello, con un micro punch electrónico, mas la
aparición de los nuevos tópicos (FINASTOPIC), ha demostrado el avance de la ciencia en el tratamiento de esta
patología.
Te dejo 70 referencias bibliográficas sobre el tema y en el adjunto fotos de ALOPECIA ANDROGÉNICA en HOMBRE y MUJER.
Saludos a todos.
Dr. Jose Lapenta.
Dr. Jose M. Lapenta.
EDITORIAL ENGLISH
===================
Hello friends of the DERMAGIC EXPRESS network today with another interesting topic, currently much discussed and studied: ANDROGENIC ALOPECIA, AND THEIR THERAPEUTIC ALTERNATIVES.
===================
Hello friends of the DERMAGIC EXPRESS network today with another interesting topic, currently much discussed and studied: ANDROGENIC ALOPECIA, AND THEIR THERAPEUTIC ALTERNATIVES.
Androgenetic alopecia (AGA), the most common type of hair loss, occurs in
80% of men and 50% of women, primarily due to genetic and hormonal
factors.
1.) HISTORY:
- In ancient Egypt (1500 BC), male pattern baldness was already known, and texts such as the Ebers Papyrus recommended home remedies such as onions, lion fat, hippopotamus fat, and bat guano.
- Hippocrates of Kos (460-370 BC), a Greek physician considered the father of Western medicine, described male pattern baldness and noted its absence in eunuchs (males whose genitals had been removed and who were therefore unable to produce the hormone testosterone).
- James B. Hamilton (1909-1990): an American dermatologist from New York, established the relationship between androgenic alopecia and androgens in 1942 while studying eunuchs, and created the first classification of this condition into 5 types.
- O'Tar T. Norwood (1920-2022): an American dermatologist from Oklahoma specializing in hair transplants, modified and expanded the scale to 7 types in 1975, after analyzing 1,000 cases.
- Erich Ludwig: a German dermatologist specializing in trichology and hair diseases, who in 1977 developed A simplified scale of FEMALE PATTERN baldness, in 3 grades, is based on the fact that hair loss in women is diffuse and central, unlike in men who present different patterns.
2.) CLASSIFICATION:
A.) MEN: (Norwood-Hamilton Scale, 7 types):
- TYPES:
I: Normal frontal hairline.
II: Mild bifrontal receding hairline.
III: Deep receding hairline (±vertex).
IV: Frontal hairline advancement + partial vertex baldness.
V: Greater hair loss, minimal hairline.
VI: Frontal-vertex fusion.
VII: Posterior "U" hairline (80% of cases).
B.) WOMEN: (Ludwig Scale, 3 grades):
I: Mild central thinning.
II: Moderate with widened parting.
III: Advanced, possible total central baldness.
This classification is for educational and comprehension purposes, which can guide the treating physician in choosing the most appropriate method to treat the condition. In women, the DIFFUSE PATTERN predominates, while in men, the most common PATTERN is U-SHAPED ALOPECIA, accounting for 80% of cases (areas of baldness from the frontal region to the mid-occipital region, sparing lateral temporal and parietal areas).
2.) ETIOLOGY:
- First, it is important to explain to the NON-MEDICAL audience that androgenic alopecia is hair loss caused by an increase in ANDROGENS (mainly testosterone) in the body, in both men and women. Specifically, it is caused by its metabolite or derivative called DIHYDROTESTOSTERONE.
- This excess of ANDROGENS, specifically DIHYDROTESTOSTERONE, is deposited in the hair follicle and causes it to atrophy, resulting in hair loss. This is the main mechanism that causes androgenetic alopecia.
- Characterized by progressive hair loss, it affects both post-pubertal men and women, and can be severe in both sexes.
- In women, conditions such as polycystic ovary syndrome (PCOS) cause an increase in androgens, leading to hair loss.
- In men, the condition undoubtedly has a GENETIC component, as not everyone is affected. It's important to know that some men will never experience androgenetic alopecia, although there is usually a history of baldness in those affected.
3.) EVOLUTION:
- It's important to explain to explain that the hair is not "ADHERED WITH GLUE" to the scalp, it has a cycle of "LIFE: ANAGEN, or growth, lasts from 1 to 7 years, CATAGEN, or transición, that lasts from 2 to 3 months and TELOGEN or resting which lasts about 3 months, then the hair falls and is replaced by a new one.
1.) HISTORY:
- In ancient Egypt (1500 BC), male pattern baldness was already known, and texts such as the Ebers Papyrus recommended home remedies such as onions, lion fat, hippopotamus fat, and bat guano.
- Hippocrates of Kos (460-370 BC), a Greek physician considered the father of Western medicine, described male pattern baldness and noted its absence in eunuchs (males whose genitals had been removed and who were therefore unable to produce the hormone testosterone).
- James B. Hamilton (1909-1990): an American dermatologist from New York, established the relationship between androgenic alopecia and androgens in 1942 while studying eunuchs, and created the first classification of this condition into 5 types.
- O'Tar T. Norwood (1920-2022): an American dermatologist from Oklahoma specializing in hair transplants, modified and expanded the scale to 7 types in 1975, after analyzing 1,000 cases.
- Erich Ludwig: a German dermatologist specializing in trichology and hair diseases, who in 1977 developed A simplified scale of FEMALE PATTERN baldness, in 3 grades, is based on the fact that hair loss in women is diffuse and central, unlike in men who present different patterns.
2.) CLASSIFICATION:
A.) MEN: (Norwood-Hamilton Scale, 7 types):
- TYPES:
I: Normal frontal hairline.
II: Mild bifrontal receding hairline.
III: Deep receding hairline (±vertex).
IV: Frontal hairline advancement + partial vertex baldness.
V: Greater hair loss, minimal hairline.
VI: Frontal-vertex fusion.
VII: Posterior "U" hairline (80% of cases).
B.) WOMEN: (Ludwig Scale, 3 grades):
I: Mild central thinning.
II: Moderate with widened parting.
III: Advanced, possible total central baldness.
This classification is for educational and comprehension purposes, which can guide the treating physician in choosing the most appropriate method to treat the condition. In women, the DIFFUSE PATTERN predominates, while in men, the most common PATTERN is U-SHAPED ALOPECIA, accounting for 80% of cases (areas of baldness from the frontal region to the mid-occipital region, sparing lateral temporal and parietal areas).
2.) ETIOLOGY:
- First, it is important to explain to the NON-MEDICAL audience that androgenic alopecia is hair loss caused by an increase in ANDROGENS (mainly testosterone) in the body, in both men and women. Specifically, it is caused by its metabolite or derivative called DIHYDROTESTOSTERONE.
- This excess of ANDROGENS, specifically DIHYDROTESTOSTERONE, is deposited in the hair follicle and causes it to atrophy, resulting in hair loss. This is the main mechanism that causes androgenetic alopecia.
- Characterized by progressive hair loss, it affects both post-pubertal men and women, and can be severe in both sexes.
- In women, conditions such as polycystic ovary syndrome (PCOS) cause an increase in androgens, leading to hair loss.
- In men, the condition undoubtedly has a GENETIC component, as not everyone is affected. It's important to know that some men will never experience androgenetic alopecia, although there is usually a history of baldness in those affected.
3.) EVOLUTION:
- It's important to explain to explain that the hair is not "ADHERED WITH GLUE" to the scalp, it has a cycle of "LIFE: ANAGEN, or growth, lasts from 1 to 7 years, CATAGEN, or transición, that lasts from 2 to 3 months and TELOGEN or resting which lasts about 3 months, then the hair falls and is replaced by a new one.
USUALLY 50 TO 100 HAIRS FALL EVERY DAY.
It is interesting that you also know that when the body is submitted to
a great STRESS,
and other factors the hair enters prematurely in the
TELOGEN PHASE
and the hair begins to fall abundantly producing a remarkable
ALOPECIA.
So factors such as the STRESS
and others that alter the hair CYCLE will contribute to the ANDROGENIC
ALOPECIA be worse.
Another factor that worsens ANDROGENIC ALOPECIA is the
SEBORRHEIC DERMATITIS
of the scalp, commonly called "INCREASE OF THE GREASE IN THE HAIR, so
that the more you use an anti-dandruff shampoo, there will be less
SEBORRHEA therefore less hair loss.
4.) TREATMENTS:
Treatments for ALOPECIA ANDROGENIC are varied, and I highlight the most
used today:
1.) MINOXIDIL, TOPICAL (ANTIHYPERTENSIVE).
2.)
FINASTERIDE
(5-ALPHA REDUCTASE INHIBITOR).
3.) DUTASTERIDE (5-ALPHA REDUCTASE INHIBITOR).
4.) FLUTAMIDE (5-ALPHA REDUCTASE INHIBITOR).
5.) CYPROTERONE ACETAT. (ORAL ANTICONCEPTIVE)
6.) SPIRONOLACTONE. (ORAL ANTIDIURETIC).
7.)
SERENOA REPENS
OR SAW PALMETTO (NATURIST, ANTI-ANDROGEN).
8.)
CYPERUS ROTUNDUS
(NATURIST).
9.) TOPICAL STEROIDS.
10.) ANTI-DANDRUFF SHAMPOO (KETOCONAZOLE, ZINC PIRYTHIONE,
BIFONAZOLE)
11.) DROSPIRENONE (ORAL ANTICONCEPTIVE).
5.) NEW TREATMENTS:
A.- TOPICAL:
- TOPICAL FINASTERIDE 0.25%: Launched in November 2024 under the name FINASTOPIC, by the Spanish laboratory ISDIN. This alternative had been sought since the 2000s and has the advantage over oral FINASTERIDE of minimizing side effects.
- CLASCOTERONE 5%: with the trade names Breezula and Winlevi: A topical androgen receptor (AR) antagonist, it blocks DIHYDROTESTOSTERONE locally without systemic effects; the product IS NOT APPROVED; it is in Phase III trials.
B.- NON-TOPICAL:
- Optimized PRP (iPRF): Fibrin-rich plasma with stem cells; 4-6 sessions per year to increase hair thickness.
- Oral minoxidil microdose (0.25-5 mg) + topical dutasteride.
- Hair mesotherapy: Microinjections of vitamins, peptides, hyaluronic acid and minoxidil.
- LLLT Laser: Low-level laser therapy, approved by the FDA in 2007 for the treatment of androgenetic alopecia, considered a safe and effective device. The available devices of this type are:
- cHairMax® LaserComb (Lexington International): The first device approved (2007). It is a red diode laser comb (655 nm) for home use.
iRestore® Laser Growth System: Approved in 2016; it is a helmet with 21 diodes and 30 infrared LEDs.
- Capillus® / LaserCap® / Theradome®: Approved between 2012 and 2018, these are cap-type lasers with a frequency of 272-560 nm.
C. HAIR TRANSPLANTATION:
Hair transplants are NOT NEW. They began to be used in the 1930s, when the Japanese physician Dr. Shoji Okuda developed the "punch" grafting technique to restore hair in burn victims and those with alopecia.
- In the 1950s, the American physician Dr. Norman Orentreich (USA) performed the first modern transplant for baldness in 1952, a "punch" type procedure.
- EVOLUTION OF THE TECHNIQUE UNTIL 2025:
- 1950s-70s: Large punch grafts (4-5mm), unattractive ("doll-like").
- 1980s-90s: Micrografts (1-4 follicles) by Dr. Bobby Limmer (FUT).
- 2000s: FUE: (2002, Dr. Rassman/FUE Research Committee).
The most widely used technique today (2025) is FUE (Follicular Unit Extraction): It extracts individual follicles (0.8-1 mm) with a motorized/robotic punch. No linear strip of skin is removed, and it leaves no visible scar. It has an 80-90% global utilization rate and offers rapid recovery.
6.) CONCLUSIONS:
There is in our body an ezyme called 5-alpha reductase that is responsible for converting TESTOSTERONE IN DIHYDROTESTOSTERONE. By increasing this metabolite, the greater the fall of hair.
Therefore, one of the strategies to avoid ANDROGENIC ALOPECIA is to inhibit the enzyme 5-alpha reductase, and for that already have been invented and discovered pharmacological and natural medicines: These are the ones already mentioned:
-
FINASTERIDE.
- DUTASTERIDE.
- FLUTAMIDA.
- SERENOA REPENS
O SAW PALMETTO (NATURIST, ANTI-ANDROGEN).
- CYPERUS ROTUNDUS
(NATURIST).
All these medicines have their ADVANTAGES and their ADVERSE EFFECTS, but
if we place ourselves in reality, science has advanced remarkably in this
field, many years ago it was popularly said:
"...TO THE FALL OF THE HAIR ONLY STOPS THE FLOOR OR SOIL .."
Today this old adage is not true, mainly due to the appearance of
drugs like DUTASTERIDE,
FINASTERIDE
and FLUTAMIDE, which inhibit the enzyme 5 alpha reductase, the main cause
of the increase of ANDROGENS in our body.
In addition, the modernization of the micro-grafting technique, where a
hair unit is transplanted with an electronic micro-punch, plus the
emergence of new topical treatments (FINASTOPIC), has demonstrated the advancement of science in the treatment of this
pathology.
I leave you 70 bibliographical references on this theme and in the
attached photos of ANDROGENIC ALOPECIA in MEN and WOMEN.
Greetings.
Dr. Jose Lapenta.
Dr. Jose M. Lapenta.
=============================================================
REFERENCIAS BIBLIOGRÁFICAS / BIBLIOGRAPHICAL REFERENCES
=============================================================
H.- Platelet-Rich Plasma in Androgenetic Alopecia (2021).
I.- New tool in our arsenal: efficacy of injectable platelet-rich fibrin (i-PRF) in androgenetic alopecia treatment (2025).
I.- New tool in our arsenal: efficacy of injectable platelet-rich fibrin (i-PRF) in androgenetic alopecia treatment (2025).
=============================================================
1.) Increased scalp skin and serum 5 alpha-reductase reduced androgens in a
man relevant to the acquired progressive kinky hair disorder and developing
androgenetic alopecia.
2.) Androgen metabolism as it affects hair growth in androgenetic alopecia.
3.) [Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?] [La finasteride: un nuovo farmaco nel trattamento dell'irsutismo e dell' alopecia androgenica maschile?]
4.) Alterations in androgen conjugate levels in women and men with alopecia.
5.) Hormonal basis of male and female androgenic alopecia: clinical relevance.
6.) [Current treatment of androgenetic male and female alopecia(with the exception of hormone treatment)] [Traitements actuels des alopecies androgenetiques masculines et feminines (traitements hormonaux exceptes).]
7.) Androgenetic alopecia: an autosomal dominant disorder.
8.) [Hair growth promoters in androgenetic alopecia. Expectations and reality] [Haarwuchsmittel bei androgenetischer Alopezie. Anspruch und Realitat.]
9.) Effects of ozonized autohaemotherapy on human hair cycle.
10.) Estrogen and progesterone receptors in androgenic alopecia versus alopecia areata.
11.) Androgens and women's health.
12.) Female androgenetic alopecia: an update.
13.) A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.
14.) Ketoconazole shampoo: effect of long-term use in androgenic alopecia.
15.) Anagen hairs may fail to replace telogen hairs in early androgenic female alopecia.
16.) Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.
17.) Safety surveillance of esterified estrogens-methyltestosterone
(Estratest and Estratest HS) replacement therapy in the United States.
18.) Balding hair follicle dermal papilla cells contain higher levels ofandrogen receptors than those from non-balding scalp.
19.) A comparison of the culture and growth of dermal papilla cells from hair follicles from non-balding and balding (androgenetic alopecia) scalp.
20.) Messenger RNA expression of steroidogenesis enzyme subtypes in thehuman pilosebaceous unit.
21.) Treatment of androgen excess in females: yesterday, today and tomorrow.
22.) Association of benign prostatic hyperplasia with male pattern baldness.
23.) Hair regrowth. Therapeutic agents.
24.) Androgenic effects of oral contraceptives: implications for patient compliance.
25.) Diffuse hypertrichosis during treatment with 5% topical minoxidil.
26.) Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells.
27.) Biphasic effects of minoxidil on the proliferation and differentiation of normal human keratinocytes.
28.) Alopecia and mood stabilizer therapy.
29.) Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride [see comments]
30.) Clinical significance of testosterone and dihydrotestosteronemetabolism in women]
31.) The 5 alpha-reductase system and its inhibitors. Recent development
and its perspective in treating androgen-dependent skin disorders.
32.) Finasteride: a clinical review.
33.) 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
34.) Genetic analysis of male pattern baldness and the 5alpha-reductase genes.
35.) Effects of topically applied spironolactone on androgen stimulated sebaceous glands in the hamster pinna.
36.) Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone.
37.) Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess.
38.) [Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization]
39.) The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
40.) Topical spironolactone reduces sebum secretion rates in young adults.
41.) Other antiandrogens.
42.) Mechanism of action and pure antiandrogenic properties of flutamide.
43.) Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
44.) Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study.
45.) A Retrospective Review of Treatment Results for Patients With Central Centrifugal Cicatrical Alopecia.
46.) The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
47.) Dutasteride in androgenetic alopecia: An update.
48.) A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
49.) New Treatments for Hair Loss.
50.) Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction.
51.) Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo.
52.) Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.
53.) Atypical post-finasteride syndrome: A pharmacological riddle.
54.) Emotional Consequences of Finasteride: Fool's Gold.
55.) The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
56.) Interventions for female pattern hair loss.
57.) Antiandrogenic Therapy with Ciproterone Acetate in Female Patients Who Suffer from Both Androgenetic Alopecia and Acne Vulgaris.
58.) Treatment of female pattern hair loss.
59.) [Spironolactone in dermatological treatment. On and off label indications].
60.) Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract.
61.) Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.
=======================================================================
2.) Androgen metabolism as it affects hair growth in androgenetic alopecia.
3.) [Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?] [La finasteride: un nuovo farmaco nel trattamento dell'irsutismo e dell' alopecia androgenica maschile?]
4.) Alterations in androgen conjugate levels in women and men with alopecia.
5.) Hormonal basis of male and female androgenic alopecia: clinical relevance.
6.) [Current treatment of androgenetic male and female alopecia(with the exception of hormone treatment)] [Traitements actuels des alopecies androgenetiques masculines et feminines (traitements hormonaux exceptes).]
7.) Androgenetic alopecia: an autosomal dominant disorder.
8.) [Hair growth promoters in androgenetic alopecia. Expectations and reality] [Haarwuchsmittel bei androgenetischer Alopezie. Anspruch und Realitat.]
9.) Effects of ozonized autohaemotherapy on human hair cycle.
10.) Estrogen and progesterone receptors in androgenic alopecia versus alopecia areata.
11.) Androgens and women's health.
12.) Female androgenetic alopecia: an update.
13.) A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.
14.) Ketoconazole shampoo: effect of long-term use in androgenic alopecia.
15.) Anagen hairs may fail to replace telogen hairs in early androgenic female alopecia.
16.) Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.
17.) Safety surveillance of esterified estrogens-methyltestosterone
(Estratest and Estratest HS) replacement therapy in the United States.
18.) Balding hair follicle dermal papilla cells contain higher levels ofandrogen receptors than those from non-balding scalp.
19.) A comparison of the culture and growth of dermal papilla cells from hair follicles from non-balding and balding (androgenetic alopecia) scalp.
20.) Messenger RNA expression of steroidogenesis enzyme subtypes in thehuman pilosebaceous unit.
21.) Treatment of androgen excess in females: yesterday, today and tomorrow.
22.) Association of benign prostatic hyperplasia with male pattern baldness.
23.) Hair regrowth. Therapeutic agents.
24.) Androgenic effects of oral contraceptives: implications for patient compliance.
25.) Diffuse hypertrichosis during treatment with 5% topical minoxidil.
26.) Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells.
27.) Biphasic effects of minoxidil on the proliferation and differentiation of normal human keratinocytes.
28.) Alopecia and mood stabilizer therapy.
29.) Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride [see comments]
30.) Clinical significance of testosterone and dihydrotestosteronemetabolism in women]
31.) The 5 alpha-reductase system and its inhibitors. Recent development
and its perspective in treating androgen-dependent skin disorders.
32.) Finasteride: a clinical review.
33.) 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
34.) Genetic analysis of male pattern baldness and the 5alpha-reductase genes.
35.) Effects of topically applied spironolactone on androgen stimulated sebaceous glands in the hamster pinna.
36.) Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone.
37.) Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess.
38.) [Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization]
39.) The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
40.) Topical spironolactone reduces sebum secretion rates in young adults.
41.) Other antiandrogens.
42.) Mechanism of action and pure antiandrogenic properties of flutamide.
43.) Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
44.) Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study.
45.) A Retrospective Review of Treatment Results for Patients With Central Centrifugal Cicatrical Alopecia.
46.) The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
47.) Dutasteride in androgenetic alopecia: An update.
48.) A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
49.) New Treatments for Hair Loss.
50.) Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction.
51.) Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo.
52.) Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.
53.) Atypical post-finasteride syndrome: A pharmacological riddle.
54.) Emotional Consequences of Finasteride: Fool's Gold.
55.) The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
56.) Interventions for female pattern hair loss.
57.) Antiandrogenic Therapy with Ciproterone Acetate in Female Patients Who Suffer from Both Androgenetic Alopecia and Acne Vulgaris.
58.) Treatment of female pattern hair loss.
59.) [Spironolactone in dermatological treatment. On and off label indications].
60.) Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract.
61.) Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.
=======================================================================
